Tag: aducanumab
FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab
If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.
Congress criticizes the FDA and the Aduhelm approval
A Congressional report on the approval of the Alzheimer's drug Aduhelm identified serious concerns about the FDA's processes
Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab)
An important decision has been made about a controversial new drug to treat Alzheimer's disease.
FDA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s
Criticism of the FDA's decision to approve aducanumab for Alzheimer's disease.
No evidence, no problem: A closer look at the aducanumab approval
Why did the FDA approve aducanumab, a drug that hasn't been shown to work?